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There is a discrepancy between the in vitro anergic
state of CD4+CD25hiFoxP3+ regulatory T (Treg) cells
and their in vivo proliferative capability. The under-
lying mechanism of this paradox is unknown. Here
we show that the anergic state of Treg cells depends
on the elevated activity of the mammalian target of
rapamycin (mTOR) pathway inducedby leptin: a tran-
sient inhibition ofmTORwith rapamycin, before T cell
receptor (TCR) stimulation, made Treg cells highly
proliferative in the absence of exogenous inter-
leukin-2 (IL-2). This was a dynamic and oscillatory
phenomenon characterized by an early downregula-
tion of the leptin-mTOR pathway followed by an
increase in mTOR activation necessary for Treg cell
expansion to occur. These data suggest that energy
metabolism, through the leptin-mTOR-axis, sets
responsiveness of Treg cells that use this information
to control immune tolerance and autoimmunity.
INTRODUCTION
A growing body of evidence suggests that the flexibility in
T cell commitment is probably not an exception but rather
the norm (Bluestone et al., 2009). The commitment to a specific
T cell phenotype, including that of naturally occurring
CD4+CD25hiFoxP3+ regulatory T (Treg) cells, depends on the
integration of numerous environmental signals received by the
T cell (Sakaguchi et al., 2008). It is well known that when some
Treg cells lose the expression of the forkhead family transcription
factor FoxP3, they also lose their suppressive capacity and can
even acquire an effector T cell phenotype (Zhou et al., 2009).
The degree of flexibility and plasticity of T cells may become
clearer with a better understanding of the molecular actions of
factors such as cytokines, antigen-presenting cells, and tran-
scription factors, which determine the fate toward defined
T cell phenotypes. Here we test the possibility that cellularIenergy metabolism can be a key element in the plasticity of
Treg cells (Zheng et al., 2009).
In humans and mice, natural Treg cells display classical
surface markers of activated T cells and proliferate in vivo
(Vukmanovic-Stejic et al., 2006). Yet, Treg cells are anergic
in vitro and fail to proliferate in response to T cell receptor
(TCR) ligation. This in vitro condition of the Treg cells appears
reversible upon TCR stimulation, in the presence of high doses
of interleukin-2 (IL-2) (Thornton and Shevach, 1998; Ng et al.,
2001).
The mammalian target of rapamycin (mTOR) is an evolution-
arily conserved 289 kDa serine-threonine protein kinase that is
inhibited by rapamycin. mTOR integrates environmental cues
from nutrients, energy, and growth factors to direct cell growth,
proliferation, and differentiation (Woods et al., 2008; Blouet et al.,
2008). In vitro, an increase in adenosine triphosphate (ATP)
increases mTOR signaling, and mTOR itself is thought to serve
as an ATP sensor working as a checkpoint for cells to sense
and decode changes in energy status, to accordingly determine
the rate of cell growth and proliferation (Faivre et al., 2006; Thom-
son et al., 2009). Although the list of downstream targets of
mTOR is continuously expanding, the most studied readouts of
mTOR function are the phosphorylation of p70S6 kinase
(p70S6K) and the S6 ribosomal protein (S6), which are direct
downstream translational regulators.
Rapamycin is an immunosuppressive drug that can promote
the expansion of Treg cells in long-term cultures in the presence
of supraphysiologic concentrations of IL-2 (Battaglia et al., 2005;
Strauss et al., 2009). Considering that IL-2 activatesmTOR (Ben-
singer et al., 2004; Zeiser and Negrin, 2008), the conundrum is
how a concomitant inactivation of mTOR by rapamycin and
IL-2-mediated activation of mTOR can result in Treg cell
proliferation.
Changes in the microenvironment directly influence the intra-
cellular energy status. Within this context, it has been hypothe-
sized that leptin, a cytokine-like hormone produced mainly by
adipocytes, might act as an endogenous ‘‘sensing’’ factor that
could act as a critical link among environment (avaibility of nutri-
ents), metabolism, and immune responses (Matarese and
La Cava, 2004). Leptin is an anorexigenic molecule with
proinflammatory activities that potentiates T helper 1 (Th1) cellmmunity 33, 929–941, December 22, 2010 ª2010 Elsevier Inc. 929
Figure 1. Freshly Isolated Human TregCells
Have Active mTOR
(A) Immunoblot for FoxP3, P-mTOR, P-p70S6K,
and P-S6 in human freshly isolated Treg cells
and in CD4+CD25 effector T cells. Graphs show
the relative densitometric quantitation of the gels
shown. One representative of five independent
experiments.
(B) Confocal microscopy of freshly isolated human
Treg cells and effector T cells stained for P-mTOR
(green) and FoxP3 (red). Representative of three
independent experiments.
(C) P-S6 expression in freshly isolated effector T
and Treg cells, respectively. Representative of
three independent experiments. The gray histo-
gram represents the isotype-matched negative
control.
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Leptin-mTOR Activation and Treg Cell Anergyproinflammatory immune responses and constrains Treg cell
proliferation (Lord et al., 1998; De Rosa et al., 2007). The neutral-
ization of leptin or its receptor (LepR) during TCR engagement
rapidly and efficiently reverses the in vitro hyporesponsiveness
of Treg cells (De Rosa et al., 2007).
Here, we examined the role of the leptin-mTOR axis (Cota
et al., 2006) in the integration of cellular energy status and lep-
tin-related signaling in both human and mouse Treg cells and
in leptin- and LepR-deficient Lepob/ob and Leprdb/db mice,
respectively. Our findings identify a dynamic role for energy
metabolism in driving the fate and responsiveness of Treg cells,
suggesting targeted manipulation of this cell subset during
immune responses.
RESULTS
Freshly Isolated Treg Cells Have an Activated Nutrient-
and Energy-Sensing mTOR Signaling Pathway
Previous studies have indicated an important role of the mTOR
pathway in Treg cell activity (Sauer et al., 2008; Haxhinasto
et al., 2008), yet the role of this energy-sensing pathway in
Treg cell anergy and proliferation has not been explored. Here
we analyzed mTOR activity in freshly isolated, purified human
CD4+CD25hiCD127FoxP3+ Treg cells (>95% pure by FACS
analysis), by using as readout the phosphorylation of the down-
stream translational regulators of mTOR, p70S6K, and S6 (Blouet930 Immunity 33, 929–941, December 22, 2010 ª2010 Elsevier Inc.a
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phosphorylation of mTOR, p70S6K, and
S6 were substantially higher in Treg cells
as compared to CD4+CD25 effector
T cells (Figure 1A), as confirmed by
confocal microscopy (Figure 1B) and
flow cytometry (Figure 1C). In vivo,
mTOR phosphorylation in sections from
nonreactive human lymph nodes was
markedly increased in FoxP3+ T cells as
compared to FoxP3 cells (Figure S1A
available online). In agreement with the
increased activation of the mTOR
pathway in Treg cells, there was a
reduced phosphorylation of the AMP-ctivated protein kinase (AMPK) (Figure S1B), a sensor of intra-
ellular energy status that negatively regulates mTOR in relation
changes in the ATP/ADP ratio (Laplante and Sabatini, 2009).
onfirming high mTOR activity and an enhanced metabolism in
reg cells, the intracellular amounts of ATP were found substan-
ally elevated in freshly isolated Treg cells (Figure S1C).
GFP-Foxp3 reporter mice confirmed an increased expression
f P-S6 by flow cytometry (Figure S1D). Taken together, these
sults indicate that freshly isolated human Treg cells display
n active mTOR pathway.
ransient mTOR Inhibition with Rapamycin, before TCR
ngagement, Reverses the Hyporesponsiveness of
unctional Treg Cells
hronic treatment with rapamycin (a selective mTOR inhibitor)
romotes expansion of Treg cells in the presence of supraphy-
iologic concentrations of IL-2 in long-term T cell cultures
vitro (Battaglia et al., 2005; Strauss et al., 2009). The molecular
vents leading to in vitro expansion of Treg cells are not clear,
lso because rapamycin and IL-2 display opposite effects on
TOR activity (Zeiser and Negrin, 2008).
We evaluated the responsiveness of Treg cells after transient
hibition of mTOR with rapamycin (without IL-2), prior to
nti-CD3 plus anti-CD28 stimulation. Acute mTOR inhibition
sulted in the reversal of Treg cell anergy and a robust prolifer-
tion with conspicuous cell clustering by 60–72 hr (Figures 2A
Figure 2. Transient mTOR Inhibition with Rapamycin, before Anti-CD3 Plus Anti-CD28 Stimulation, Associates with Proliferation of Func-
tional Human Treg Cells that Upregulate FoxP3 Expression
(A) Proliferation of Treg cells pretreated or not with rapamycin, before anti-CD3 plus anti-CD28 mAb stimulation. Data are shown as mean ± SD (n = 20,
*p < 0.0001).
(B) Contrast-phase microscopy showing clustering and activation of Treg cells pretreated or not with rapamycin. Representative experiment of ten.
(C) IL-2 secretion by Treg cells pretreated or not with rapamycin, upon anti-CD3 plus anti-CD28 stimulation. The data are shown asmean ± SD (n = 4, *p < 0.001).
(D) Proliferation of Treg cells pretreated or not with rapamycin in the presence or absence of IL-2 neutralizing mAb. The data are shown as mean ± SD (n = 4,
*p < 0.001).
(E) Proliferative response at 36 hr of CFSE-labeled effector T cells alone (left) or in coculture with untreated (middle) or rapamycin-pretreated (right) unlabeled Treg
cells. Representative of three independent experiments (*p < 0.0001, **p < 0.001 when compared to CD4+CD25CFSE+).
(F) FoxP3 expression in Treg cells pretreated or not with rapamycin, after 36 hr stimulation with anti-CD3 plus anti-CD28. Representative of six independent
experiments (*p < 0.01, as compared with anti-CD3 plus anti-CD28).
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Leptin-mTOR Activation and Treg Cell Anergyand 2B). Whereas both acute and chronic treatment with rapa-
mycin reduced the proliferation of effector T cells (Figures S2A
and S2B), Treg cells proliferation did not occur during chronicIrapamycin treatment when exogenous IL-2 was not present
(Figure S2E). Thus, Treg cells appear more sensitive to a short
or transient perturbation of the mTOR pathway than effectormmunity 33, 929–941, December 22, 2010 ª2010 Elsevier Inc. 931
Immunity
Leptin-mTOR Activation and Treg Cell AnergyT cells. To confirm specificity for mTOR, we transiently inhibited
the mitogen-activated protein kinase (MAPK) pathway with
UO126, and no substantial induction of Treg cell proliferation
was observed (Figure S2F).
The reversal of Treg cell anergy after acute reatment with ra-
pamycin associated with an increased production of IL-2 by the
Treg cells, and it was abolished by the addition of an IL-2
neutralizing antibody (Figures 2C and 2D), indicating IL-2
dependency for the rapamycin-induced Treg cell expansion.
Opposite phenomena were observed in effector T cells (Figures
S2C and S2D). The effects were specific for the Treg cells and
could not be ascribed to IL-2 secretion by non-Treg cells, as
indicated by flow cytometry for intracellular IL-2 production at
early time points (Figures S2G and S2H). Also, the mTOR-
treated proliferating Treg cells increased the expression of
FoxP3 at 36–48 hr and maintained their suppressive phenotype
(Figures 2E and 2F). The expression of the activation marker
CD25 on CFSE-labeled effector T cells (Figure S2I) and that
of CD39, CD71, CTLA-4, GITR, and CCR7 were upregulated
on the proliferating Treg cells after transient mTOR inhibition
in the 36 hr cultures (Figure S2J). All together, these data
suggest that transient mTOR inhibition with rapamycin, before
anti-CD3 plus anti-CD28 stimulation, associates with prolifera-
tion of functional human Treg cells that upregulate FoxP3
expression.
In Vivo Transient Inhibition of mTOR Enhances Treg Cell
Proliferation and Ameliorates Autoimmune
Encephalomyelitis
Treg cells, despite an in vitro hyporesponsiveness, can prolif-
erate in vivo (Vukmanovic-Stejic et al., 2006). To evaluate
whether acute and transient mTOR inhibition could also enhance
in vivo Treg cell proliferation, we treated EGFP-FoxP3 reporter
mice with BrdU, to follow in vivo Treg cell proliferation both in
basal conditions and after antigen immunization with complete
Freund’s adjuvant, CFA. We injected a single dose of rapamycin
into naive EGFP-FoxP3 mice and, 12 hr before CFA priming, into
another group of immunized EGFP-FoxP3 mice (Figure 3A).
Interestingly, the percentage and absolute numbers of EGFP-
FoxP3 cells were increased by rapamycin pretreatment, at
a higher degree after immunization with CFA (Figure 3B). The
increased numbers of EGFP-FoxP3 cells were due to prolifera-
tion, as suggested by BrdU incorporation (Figure 3C), both in
the peripheral blood (Figure S3A) and in the draining lymph no-
des (Figure 3C). Thus, also in vivo a transient mTOR inhibition
enhances Treg cell expansion. Conversely, chronic treatment
with rapamycin—in the absence of elevated IL-2—did not induce
proliferation of Treg cells in naive and immunized mice (Figures
S3B and S3C).
To expand the findings to an autoimmune model, we evalu-
ated whether acute rapamicin pretreatment, 12 hr before
priming with self-antigen, could affect clinical onset and
progression of autoimmune encephalomyelitis (EAE), an animal
model of multiple sclerosis. Relapsing-remitting EAE (RR-
EAE)-susceptible SJL/J female mice were immunized with
proteolipid protein peptide (PLP139-155) preceded either by
PBS or rapamycin treatment. Transient mTOR inhibition, before
autoantigen immunization, led to a statistically significant reduc-
tion in RR-EAE clinical score during the subsequent 30 days of932 Immunity 33, 929–941, December 22, 2010 ª2010 Elsevier Inc.observation (Figure 3D). These beneficial effects on EAE onset
and progression associated with an increased frequency of
Treg cells that preceded the peak of the disease in rapamycin-
pretreated mice (Figure 3E). These data indicate that also
in vivo transient mTOR inhibition with rapamycin increases
Treg cell proliferation in EGFP-FoxP3 mice and ameliorates
the progression of RR-EAE.
Hyperactivation of mTOR In Vitro Results in
Hyporesponsiveness of Treg Cells and Is also Necessary
for Their Proliferation over Time
The early molecular events induced by transient inhibition of the
mTOR pathway in human Treg cells were studied in 1 hr cultures
(Figure 4). The extracellular signal-regulated kinases 1 and 2
(ERK1 and ERK2) and the cell cycle inhibitor p27kip1 reflected
the anergic state of the Treg cells after treatment with anti-CD3
plus anti-CD28 (De Rosa et al., 2007), whereas after TCR stimu-
lation, the inhibition of mTOR induced the activation of ERK1 and
ERK2 and the degradation of the pre-existing high amounts of
p27kip1 (which associated with cell cycle arrest in the Treg cells)
(Figure 4A; Figure S4A). High phosphorylation of mTOR in Treg
cells did not change after TCR stimulation, and rapamycin
decreased the phosphorylation of mTOR, p70S6K, and S6 (Fig-
ure 4B; Figure S4B). These data suggest that the reduction of
mTOR activity, before TCR engagement, is necessary to allow
Treg cells to enter cell cycle, exiting their anergic state.
Next, we evaluated whether mTOR inhibition could alter TCR
signaling. Rapamycin pretreatment reduced the phosphorylation
of Lck Tyr505 (an inhibitory tyrosine of the TCR-Lck kinase
activity) (Figure 4C; Figure S4C). This event associated with
a concomitant increase in Zap-70 phosphorylation, in agreement
with induction of Treg cell proliferation (Figure 4C; Figure S4C).
These findings suggest that transientmTOR inhibitionmodulates
the TCR signaling in Treg cells.
Further, we examined the phosphoinositide-3-kinase (PI3K)-
protein kinase B (PKB or AKT) pathway downstream of the
TCR activation. Ser473 phosphorylation of AKT was increased
by rapamycin pretreatment upon TCR engagement (Figure 4C;
Figure S4C). Because we previously showed an early IL-2 secre-
tion by rapamycin-pretreated Treg cells, we analyzed STAT5
phosphorylation (as a major element of transduction for IL2-R
signaling) (Burchill et al., 2007; Yu et al., 2009). Unstimulated
Treg cells had high amounts of phospho-STAT5 that were main-
tained high upon TCR stimulation; on the contrary, rapamycin
pretreatment led to loss in STAT5 phosphorylation and a subse-
quent induction upon TCR engagement (Figure 4C; Figure S4C).
These data suggest that the high metabolic rate of Treg cells, as
testified by active mTOR pathway, correlates with high STAT5
activity and Treg cell hyporesponsiveness in vitro.
Concomitantly with the suppression of mTOR activity, FoxP3
expression was reduced in Treg cells after mTOR inhibition
(Figure 4C; Figure S4C). Because FoxP3 suppresses IL-2 gene
transcription (Schubert et al., 2001), the rapamycin-induced tran-
sient downregulation of FoxP3 could account for the observed
IL-2 production and reversal of Treg cell anergy (Figures 2C
and 2D), a result in agreement with an early downmodulation of
STAT5 phosphorylation and subsequent induction by anti-CD3
plus anti-CD28 stimulation. In vivo, confocal microscopy of
human nonreactive lymph nodes indicated that FoxP3+ T cells
Figure 3. In Vivo Transient mTOR Inhibition
with Rapamycin Increases Treg Cell Prolif-
eration in EGFP-FoxP3 Mice and Amelio-
rates RR-EAE
(A) Schematic model of the experimental design.
In brief, EGFP-FoxP3 reporter mice were daily
treated with BrdU in basal conditions and upon
antigen immunization with CFA and were injected
with a single dose of rapamycin or vehicle, 12 hr
before CFA priming, to follow proliferation of
EGFP-FoxP3 cells overtime. Blood samples were
obtained at 5 days and draining lymph nodes
were harvested at days 8 and 12, respectively.
(B) Absolute number and percentage of EGFP-
FoxP3 cells gated on CD4+ cells in the lymph no-
des from mice pretreated or not with rapamycin,
immunized or not with CFA. The data are shown
as mean ± SD (n = 6, *p < 0.01).
(C) Flow cytometry for BrdU incorporation in
EGFP-FoxP3 cells from the lymph nodes of
EGFP-FoxP3 mice in vivo pretreated (red line) or
not (black line) with rapamycin, in unimmunized
or after 8 and 12 days immunization with CFA.
Representative of three independent experiments
(*p < 0.01, **p < 0.001 when compared with
vehicle). The gray histogram represents the iso-
type-matched negative control.
(D) Mean clinical score of RR-EAE in SJL/J female
mice immunized with PLP139-155 preceded either
by vehicle or 12 hr rapamycin pretreatment. Data
are representative of two independent experi-
ments with similar results (n = 5 mice per group,
*p < 0.01).
(E) Percentage of FoxP3+ cells gated onCD4+ cells
isolated from the lymph nodes of SJL/J mice
immunized with PLP139-155 peptide, pretreated or
not with rapamycin before PLP139-151 priming.
The data are shown as mean ± SD (n = 5 mice
per group, *p < 0.01).
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Leptin-mTOR Activation and Treg Cell Anergyhad high amounts of phosphorylated mTOR, whereas reactive
(proliferating) lymph nodes, positive for ki67, displayed amarked
reduction of mTOR phosphorylation in the substantially elevated
numbers of FoxP3+ T cells (Figures 4D–4F).Immunity 33, 929–941, DLate molecular events (at 60–72 hr) of
mTOR activity in proliferating Treg cells,
after rapamycin treatment (Figure 4G),
were analyzed by confocal microscopy
and flow cytometry (Figures 4H and 4I).
In contrast to the initial phases, actively
proliferating Treg cells displayed high
amounts of mTOR and S6 phosphoryla-
tion (Figures 4H and 4I), suggesting that
an increased mTOR activity is required
to sustain Treg cell proliferation over
time. This would be in agreement with
the possibility of an increased require-
ment of nutrients for Treg cells during
proliferation. To corroborate the findings
in vivo, EGFP-FoxP3 mice were immu-
nized with CFA, pretreated or not with
rapamycin 12 hr before antigen priming.After 8 days, draining lymph nodes from mice were cultured in
the presence of BrdU after PPD stimulation for 48 hr. EGFP-
FoxP3 cells from mice pretreated in vivo with rapamycin had
a substantially higher BrdU incorporation than EGFP-FoxP3 cellsecember 22, 2010 ª2010 Elsevier Inc. 933
Figure 4. Early and Late Molecular Events
Induced by mTOR Inhibition in Human and
Mouse Treg Cells
(A–C) Immunoblot for P-ERK and p27Kip1 (A),
P-mTOR, P-p70S6K, P-S6 (B), and P-Lck, P-Zap-
70, P-AKT, P-STAT5, and FoxP3 (C) on human
Treg cells pretreated or not with rapamycin and
then stimulated with anti-CD3 plus anti-CD28 for
1 hr. One representative out of five independent
experiments.
(D) Serial sections from nonreactive human lymph
nodes (top) or reactive human lymph nodes
(bottom) stained for Ki67, P-mTOR, and FoxP3.
(E and F) Number of FoxP3+ T cells (E) and expres-
sion of P-mTOR (F) in both reactive and nonreac-
tive human lymph nodes. One representative out
of three independent experiments is shown
(*p < 0.005, **p < 0.001).
(G) Proliferation of Treg cells pretreated or not with
rapamycin, upon anti-CD3 plus anti-CD28 stimu-
lation. The data are shown as mean ± SD
(n = 20, *p < 0.0001).
(H) Confocal microscopy on Treg cells pretreated
or not with rapamycin, after 36 hr of anti-CD3
plus anti-CD28 stimulation, stained for P-mTOR
(green) and FoxP3 (red). Representative of three
independent experiments.
(I) Flow cytometry for P-S6 expression in Treg cells
pretreated (red line) or not (black line) with rapamy-
cin, after 36 hr stimulation with anti-CD3 plus anti-
CD28. Representative of three independent
experiments (*p < 0.01 when compared with
vehicle). The gray histogram represents the iso-
type-matched negative control.
(J) Percentage of BrdU-positive cells gated on
CD4+EGFP-FoxP+ cells from lymph nodes of
immunized EGFP-FoxP3 mice in vivo pretreated
or not with rapamycin, and then in vitro stimulated
with PPD. The data are shown as mean ± SD
(n = 3, *p < 0.01).
(K) Flow cytometry for P-S6 expression in EGFP-
FoxP cells gated on CD4+ cells from lymph nodes
of immunized EGFP-FoxP3mice in vivo pretreated
(red line) or not (black line) with rapamycin, and
then stimulated in vitro with PPD. Representative
of three independent experiments (n = 3,
*p < 0.01 when compared with vehicle).
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Leptin-mTOR Activation and Treg Cell Anergyof control mice (Figure 4J), associated with higher amounts of S6
phosphorylation (Figure 4K). To addresswhether an oscillation of
the mTOR pathway (early downmodulation and subsequent
upregulation) associates with induction and maintenance of
Treg cell proliferation, we silenced mTOR expression in Treg934 Immunity 33, 929–941, December 22, 2010 ª2010 Elsevier Inc.w
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pcells through infection with lentivirus en-
coding shRNA sequences targeting the
Frap1 gene (that encodes for mTOR).
mTOR silencing did not allow Treg cells
to unlock their hyporesponsive state
upon anti-CD3 plus anti-CD28 stimula-
tion (Figure S4D), because of inability to
reactivate mTOR—essential for the
maintenance of Treg cell proliferation
(Figure S4D). This finding is in agreementith the evidence that chronic mTOR inhibition (and not tran-
ient) does not induce Treg cell proliferation in the absence of
igh amount of exogenous IL-2 (Figure S2E). The above findings
uggest the existence of an oscillatory loop in the mTOR
athway that plays a role in Treg cell responsiveness.
Immunity
Leptin-mTOR Activation and Treg Cell AnergyLeptin Contributes to the Activation of the mTOR
Pathway in Treg Cells
We have previously shown that leptin produced by Treg cells
constrains their proliferation and that neutralization of leptin
during the activation of Treg cells reverses their state of hypores-
ponsiveness (De Rosa et al., 2007). Because this phenomenon
resembles the reversal of Treg cell anergy induced by the tran-
sient inhibition of mTOR with rapamycin (Figure 5A), we studied
whether leptin could influence rapamycin-induced Treg cell
proliferation. The addition of leptin to rapamycin-expanding
Treg cells inhibited their proliferation (Figure 5B). To also address
whether the high metabolic rate of freshly isolated human Treg
cells was associated with mTOR activation secondary to leptin
secretion, we measured the amount of phosphorylation of S6
before and after leptin neutralization of unstimulated Treg cells.
Interestingly, the high amounts of active S6 were substantially
reduced by leptin blockade (Figure 5C). Specificity was
confirmed by partial reversal of inhibition after the addition of
recombinant leptin to leptin-neutralized Treg cells (Figure 5C).
These results suggest a link between an autocrine secretion of
leptin and mTOR activation in Treg cells (Figure 5C). To further
evaluate the effects of leptin on mTOR (Figure 5D; Figure S5A),
we treated unstimulated Treg cells with recombinant leptin—
with or without pretreatment with rapamycin. In both cases, lep-
tin activated mTOR, increased S6 phosphorylation, and had little
effect on p70S6K.
The role of leptin on mTOR pathway was then evaluated
ex vivo by studying S6 phosphorylation in Treg cells isolated
from leptin-deficient Lepob/ob mice treated or not with leptin (Fig-
ure 5E). A direct induction of P-S6 was detected at 2 hr in
response to leptin. Time course experiments (0–12 hr) with
vehicle, rapamycin, and leptin (Figures 5F and 5G) in wild-type
(wt) and Lepob/ob mice showed that rapamycin reduced S6
phosphorylation in both groups of mice when compared to
vehicle-treated mice. Conversely, leptin administration induced
a significant activation of the mTOR pathway and increased
phosphorylation of S6 only in Treg cells from Lepob/ob mice
(Figure 5G).
Because leptin is a metabolic parameter that reflects the nutri-
tional state and the amount of food stored as fat, we evaluated in
mice how 48 hr acute starvation—which dramatically reduces
circulating leptin, body fat, and immune function (Lord et al.,
1998)—could influence Treg cell responsiveness in vivo and
in vitro by modulating the mTOR pathway. To this purpose,
EGFP-FoxP3 mice were starved for 48 hr in the presence or
not of administered recombinant leptin and compared with ad
libitum fed mice. Starvation substantially decreased both body
weight and serum leptin (Figures S5B and S5C). An increase in
EGFP-FoxP3 cells (Figure 5H) associated with a dramatic
reduction in S6 phosphorylation in starved mice, partly reversed
by recombinant leptin replacement (Figure 5I), suggesting that
also in vivo there is a direct link between leptin and the mTOR
pathway in Treg cells. Strikingly, EGFP-FoxP3 cells from starved
mice stimulated in vitro with anti-CD3 plus anti-CD28 had higher
proliferation (as BrdU incorporation) when compared with ad
libitum fed and starved mice treated with recombinant leptin
(Figure 5J). Taken together, these data suggest that the modula-
tion of leptin through acute starvation can be a strategy to unlock
Treg cell hyporesponsiveness, by acting on the mTOR pathway.ITransient Inhibition of mTOR with Rapamycin Inhibits
the Expression of Leptin and LepR in Treg Cells
Unstimulated Treg cells expressed leptin and LepR, and
pretreatment with rapamycin reduced both the intracellular
leptin and the cell surface expression of LepR (Figure 6A), as
confirmed by mRNA expression by real-time PCR (Figure 6B).
This was even more evident after activation with anti-CD3 plus
anti-CD28, where leptin increase (Figures 6A and 6B) associated
with high mTOR activity (Figure 4B). Rapamycin pretreatment
reduced leptin and LepR expression in stimulated Treg cells
(Figures 6A and 6B), as confirmed by ELISA (Figures 6C and
6D). These results suggest that rapamycin can unlock Treg cell
hyporesponsivenes by reducing mTOR activation and inhibiting
leptin secretion.LepR Deficiency Associates with a Reduced mTOR
Activity and the Proliferation of Treg Cells
The early molecular events related to mTOR activity in Treg cells
were evaluated in congenitally LepR-deficient Leprdb/db mice
versus Leprdb/+ heterozygous controls (Figure 7). Treg cells
from Leprdb/db mice had higher expression of FoxP3 before
and after TCR-mediated stimulation (Figure 7A; Figure S6A),
confirming that LepR deficiency associated with elevated
numbers of Treg cells (De Rosa et al., 2007). In Treg cells from
heterozygous Leprdb/+ controls, mTOR activity was high before
and after TCR stimulation, and this event associated with anergy
of Treg cells, as confirmed by lack of proliferation, little ERK1 or
ERK2 phosphorylation, and lack of p27kip1 degradation (Figures
7B–7D; Figures S6A–S6C). Conversely, in Treg cells from
Leprdb/db mice, mTOR, p70S6K, and S6 phosphorylation were
significantly reduced, and a lack of induction and maintenance
of mTOR phosphorylation was found after anti-CD3 plus anti-
CD28 stimulation, indicating a reduced mTOR activity in the
absence of LepR responsiveness (Figure 7B; Figure S6B). These
events in Leprdb/db mice associated with proliferation in Treg
cells, together with higher ERK1 and ERK2 phosphorylation
and increased degradation of p27kip1 (Figures 7C and 7D;
Figure S6C).
At late time point of Treg cell proliferation (36–48 hr), higher
induction of P-S6 was observed in Leprdb/db mice despite
modest activation of this pathway at early stages (1 hr) (Fig-
ure 7E). Also, the 2-fold increase in S6 phosphorylation seen
after TCR-mediated stimulation was not present in anergic
Treg cells from Leprdb/+ ccontrol mice thatmaintained constantly
high mTOR amounts (Figures 7F and 7G). These data suggest
that alterations (reductions) of LepR-related signaling can
enhance the proliferative potential of Treg cells and render
them responsive to TCR stimulation.DISCUSSION
Here we show that a link between energy status and Treg cell
responsiveness is the leptin-mTOR signaling pathway. Overex-
pression of leptin-mTOR in freshly isolated Treg cells is respon-
sible for their state of hyporesponsiveness. Although transient
mTOR inhibition with rapamycin reduced proliferation of effector
CD4+CD25 T cells, this condition led to proliferation of
functional Treg cells.mmunity 33, 929–941, December 22, 2010 ª2010 Elsevier Inc. 935
Figure 5. Leptin Contributes to mTOR Pathway Activation in Human and Mouse Treg Cells
(A) Proliferation of human Treg cells pretreated or not with rapamycin or anti-leptin neutralizingmAb or both, before anti-CD3 plus anti-CD28 stimulation. The data
are shown as mean ± SD (n = 20, *p < 0.0001).
(B) Proliferation of Treg cells pretreated or not with rapamycin before treatment with leptin (100 ng/ml) before anti-CD3 plus anti-CD28 stimulation. The data are
shown as mean ± SD (n = 10, *p < 0.0001, **p < 0.001).
(C) P-S6 expression (black line) in unstimulated Treg cells, freshly isolated (left), or anti-leptin pretreated in the absence (middle) or in the presence of exogenous
leptin (right), at 1 hr time point. Representative of three independent experiments (*p < 0.01 when compared with vehicle). The gray histogram is the isotype-
matched negative control.
(D) Immunoblot for P-mTOR, P-p70S6K, and P-S6 on unstimulated Treg cells pretreated or not with rapamycin and then treated or not with leptin for 1 hr. One
representative out of five independent experiments.
(E) Ex vivo P-S6 expression in Treg cells from Lepob/ob mice treated or not with leptin after 2 hr from intreperitoneal injection (n = 3 mice/group, representative of
three independent experiments).
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Immunity
Leptin-mTOR Activation and Treg Cell AnergyOne question is how rapamycin, which is an inhibitor of cell
growth and proliferation used to block tumor cell growth and
transplant rejection, can concomitantly reduce the proliferation
of T cells and promote the proliferation of Treg cells. It is likely
that dosage and timing may both be responsible in a scenario
in which the intracellular metabolic state can control Treg cell
responsiveness through the leptin-mTOR axis. As the metabolic
state of a cell changes along with activation, rapamycin might
differentially affect Treg cell reactivity depending on the
metabolic state, and mTOR blockade on effector and Treg cells
would associate with a differential outcome in the two cellular
subsets. Treg cells have a high metabolic state and high ATP
and mTOR activity, and are unresponsive to proliferative stimuli,
whereas effector T cells have a low metabolic state associated
with normal responsiveness. Of interest, the current findings
suggested that the transient inhibition of the leptin-mTOR
pathway, before TCR stimulation, promoted TCR-induced prolif-
eration in Treg cells, yet at later time points an intact mTOR
activity is necessary to sustain Treg cell proliferation. One
possible explanation could be that Treg cells need a low meta-
bolic rate to enter cell cycle and start proliferation, whereas
proliferation would be maintained by the presence of nutrients
and growth factors that induce mTOR (which in turn controls
their cellular transport and trafficking) (Faivre et al., 2006; Thom-
son et al., 2009; Woods et al., 2008; Blouet et al., 2008; Yang
and Guan, 2007).
The findings of this study support a mechanism of cross-regu-
lation between metabolism and Treg cell responsiveness where
an ‘‘oscillatory’’ switch in mTOR activity can control responsive-
ness of Treg cells. These results are in agreement with a recent
report showing an evolutionarily conserved mechanism of inter-
action between metabolism and genes of innate immunity in
Drosophila, in which genes are activated under normal physio-
logical conditions in response to the oscillating energy status
of cell and tissues (Becker et al., 2010). The ‘‘oscillation’’ in the
mTOR pathway activity may be necessary for Treg cell prolifera-
tion because when the pathway is constantly inhibited either by
chronic rapamycin treatment or by mTOR gene silencing, cells
are unable to reactivate it, so that proliferation does not occur.
Biochemical analyses showed that transient inhibition of
mTOR ‘‘unlocked’’ Treg cell hyporesponsiveness via a rapid
and early downmodulation of FoxP3 and the cell cycle inhibitor
p27kip1, together with phosphorylation of ERK1 and ERK2.
Considering that FoxP3 inhibits Il2 gene transcription and
p27kip1 maintains cell cycle arrest in Treg cells (Schubert et al.,
2001), the early downmodulation of thesemolecules would allow
Treg cells to enter the G1/S phase of the cell cycle and induce
IL-2 gene transcription. At later time points (36 hr), the increased
IL-2 secretion after proliferation would possibly induce FoxP3(F and G) Time course of fold changes in P-S6 expression in Treg cells from wt (F
(red line) or leptin (black line), as compared with vehicle-treated mice. Representa
(H) Percentage of EGFP-FoxP3 cells gated on CD4+ cells from lymph nodes of ad
sentative of two independent experiments (n = 3 mice/group).
(I) P-S6 expression (black line) in EGFP-FoxP3 cells gated on CD4+ cells from lym
mice. Representative of two independent experiments (n = 3 mice/group, *p < 0.0
The gray histogram is the isotype-matched negative control.
(J) Flow cytometry for BrdU incorporation in EGFP-FoxP3 cells from the lymph no
and then stimulated in vitro with anti-CD3 plus anti-CD28. Representative of two
**p < 0.05 compared with 48 hr fasted). The gray histogram represents the isoty
Iexpression in Treg cells. We also observed that in Treg cells
there is a block in TCR signaling as suggested by the low
Zap-70 phosphorylation and high amounts of the inhibitory
Tyr505 Lck after TCR stimulation. Interestingly, transient mTOR
inhibition unlocked TCR signaling by reducing the Lck inhibitory
feedback and by restoring Zap-70 phosphorylation. These
events were also able to induce a AKT signaling secondary to
TCR engagement. Finally, we investigated the STAT5 molecule,
as major element of IL-2R signal transduction (Burchill et al.,
2007; Yu et al., 2009); Treg cells showed costitutively high
amounts of phospho-STAT5 independently by TCR stimulation,
in agreement with their high metabolic rate, high FoxP3 expres-
sion, and high CD25 (IL-2Ra) expression. Rapamycin pretreat-
ment was able to affect STAT5 phosphorylation: it was first
completely abolished and subsequently reinduced upon TCR
engagement, confirming also the increase in IL-2 secretion by
proliferating Treg cells. Taken together, these events further
confirm the need of perturbing the metabolic rate of Treg cells
to allow their in vitro proliferation.
We have previously shown that Treg cells produce leptin that
constrains their own proliferation (De Rosa et al., 2007). Here we
further those findings by showing that leptin produced by Treg
cells contributes to the activation of the mTOR pathway in Treg
cells. In the crosstalk between leptin and mTOR in Treg cells, ra-
pamycin and subsequent transient mTOR inhibition substantially
inhibit leptin secretion and LepR expression on Treg cells. Also,
the evidence that EGFP-FoxP3 cells from starved mice prolifer-
ated in vitro, concomitantly with the transient reduction in serum
leptin-mTOR activation, suggests that leptin may link mTOR
activity to the anergic state of Treg cells in vitro.
The so-called frugal phenotype, in which the survival of chron-
ically food-restricted mice is higher than in ad libitum fed mice,
may fit with the possibility of a reciprocal influence between
nutritional-metabolic state and immune responses (Matarese
and La Cava, 2004; Matarese et al., 2008). In Lepob/ob and
Leprdb/db mice, which have higher numbers of Treg cells
secondary to the absence of leptin signaling (De Rosa et al.,
2007), early kinetics (0–12 hr) of mTOR activation in Treg cells
showed that leptin determined a 2- to 3-fold induction of P-S6
in Lepob/ob mice, rapidly subsiding after 12 hr when compared
with wt mice. A different induction versus inhibition of the P-S6
pathway in wt versus Lepob/ob mice could be ascribed to the
leptin already present in wt mice, whereas in Lepob/ob mice the
chronic leptin deficiency would make the Treg cells more sensi-
tive to mTOR activation after leptin administration. Interestingly,
Treg cells in Leprdb/db mice had higher FoxP3 expression, lower
mTOR activation, and increased in vitro responsiveness, sug-
gesting that the absence of LepR impairs mTOR activation and
renders Treg cells responsive to in vitro TCR stimulation. Once) or leptin-deficient Lepob/ob mice (G), intraperitoneally injected with rapamycin
tive of three independent experiments (*p < 0.01 when compared with vehicle).
libitum fed, 48 hr fasted, and 48 hr fasted + leptin EGFP-FoxP3 mice. Repre-
ph nodes of ad libitum fed, 48 hr fasted, and 48 hr fasted + leptin EGFP-FoxP3
1 when compared with ad libitum fed; **p < 0.05 compared with 48 hr fasted).
des of ad libitum fed, 48 hr fasted, and 48 hr fasted + leptin EGFP-FoxP3 mice,
independent experiments (n = 3, *p < 0.01 when compared with ad libitum fed;
pe-matched negative control.
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Figure 6. Rapamycin Pretreatment Reduces the Expression of Leptin and LepR in Treg Cells
(A) Confocal microscopy of human Treg cells pretreated or not with rapamycin, in presence or absence of anti-CD3 plus anti-CD28 stimulation, stained for LepR
(red) and leptin (green). Representative of three independent experiments.
(B) Real-time PCR for leptin in human Treg cell pretreated or not with rapamycin, in the presence or absence of anti-CD3 plus anti-CD28 stimulation. The data are
shown as mean ± SD (n = 5, *p < 0.05; **p < 0.0001; ***p < 0.001).
(C) Dot plots show beads-based ELISA for leptin in cell supernatant from Treg cells, pretreated or not with rapamycin, in the presence or not of anti-CD3 plus
anti-CD28 stimulation. Representative of three independent experiments.
(D) Graph shows quantitation of leptin production in cell supernatant from Treg cells in all the above conditions. The data are shown as mean ± SD (n = 3,
*p < 0.0001).
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Leptin-mTOR Activation and Treg Cell AnergyTreg cell proliferation occurred, mTOR induction was higher in
Treg cells from Leprdb/db mice than in Treg cells from wt animals.
Recent reports have shown an involvement of the mTOR
pathway in the control of TCR-dependent FoxP3 expression
(Sauer et al., 2008), in the de novo differentiation of Treg cells
(Haxhinasto et al., 2008), and in the decision between effector
T and Treg cell lineage commitment (Delgoffe et al., 2009). We
suggest that the leptin-mTOR axis might integrate cellular
energy status with metabolic-related signaling in Treg cells,
envisioning the possibility that a tuned control of energy could
be used to manipulate Treg cell homeostasis. Indeed, in neural
circuits the leptin-mTOR pathway drives the choices between
food intake and fasting by controlling energy status (Gao and
Horvath, 2008; Abizaid et al., 2006). In the hypothalamus, leptin938 Immunity 33, 929–941, December 22, 2010 ª2010 Elsevier Inc.inhibits food intake through mTOR activation, and mTOR inhibi-
tion with rapamycin prevents leptin-induced anorexia (Cota
et al., 2006). Finally, neural cells are refractory to restimulation
after a primary neural stimulation, which is somewhat similar to
the finding of mTOR-mediated unresponsiveness after in vitro
TCR stimulation of Treg cells that are metabolically active (McIn-
tyre et al., 2004).
Current strategies to expand Treg cells with rapamycin
employ ex vivo addition of supraphysiologic concentrations of
IL-2 (500–1000 UI/ml) to cultured cells during TCR stimulation
(Gregori et al., 2007). The addition of rapamycin to Treg cells
during TCR stimulation (and not pretreatment and removal, as
we performed in this report) is not sufficient to induce prolifera-
tion of Treg cells but rather inhibits their expansion. Instead,
Figure 7. Treg Cells from LepR-Deficient
Leprdb/dbMice Have ReducedmTORActiva-
tion Concomitantly with a Higher Prolifera-
tive Capacity
(A–C) Immunoblot for FoxP3 (A), P-mTOR,
P-p70S6K, P-S6 (B), and P-ERK and p27Kip1 (C) in
Treg cells from Leprdb/+ lean controls and leptin-
receptor-deficient Leprdb/db mice stimulated or
not with anti-CD3 plus anti-CD28 for 1 hr. One
representative out of four independent experi-
ments.
(D) Proliferation of Treg cells from Leprdb/+ and
Leprdb/db mice, stimulated or not with anti-CD3
plus anti-CD28 mAb. The data are shown as
mean ± SD (n = 10, *p < 0.0001).
(E) P-S6 expression in Treg cells from Leprdb/+
(black line) or Leprdb/db (red line) mice in the pres-
ence or absence of anti-CD3 plus anti-CD28 in
36 hr culture. Representative of three independent
experiments. The gray histogram represents the
isotype-matched negative control.
(F and G) P-S6mean fluorescence intensity in both
strains of mice with or without anti-CD3 plus anti-
CD28 stimulation (F) and fold change in P-S6 (G).
(*p < 0.01 when compared with unstimulated
cells.) Leprdb/db mice had a much higher P-S6
induction than heterozygote controls during prolif-
eration. Representative of three independent
experiments.
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rapamycin for long-term cultures (generally 7–10 days). Thus,
on the one hand rapamycin lowers the metabolic state of Treg
cells, rendering them prone to proliferate. On the other hand,
high doses of IL-2 inducemTOR activation that permits transport
of nutrients, once the G1/S phase transition has been induced by
TCR stimulation. In other terms, mTOR activation (high meta-
bolic rate) determines Treg cell hyporesponsiveness but also
maintains their expansion at later time points. This model is
consistent with that of the mTOR pathway involvement in the
control of proliferation of hematopoietic stem cells (HSCs)
(Chen et al., 2008), where mTOR deletion drives HSCs from
quiescence into cell cycling and proliferation. All this suggests
that a high metabolic rate contrasts cell cycle transition from
G1 to S phase, whereas a low metabolic rate (i.e., through rapa-
mycin) promotes proliferation. The notion that the metabolic
state in Treg cells can affect their proliferation and suppressive
function is also supported by the high amounts of intracellular
cyclic adenosine-30-50-monophosphate (cAMP) in Treg cells
(cAMP participates in the metabolic activation of mTOR, result-
ing in an enhanced ATP production) (Kwon et al., 2004), and
our data are in line with a report showing that Treg cells have
high amounts of mTOR in a graft-verus-host murine model
(Zeiser and Negrin, 2008). The metabolic control of immune
response in CD8+ T cells (Araki et al., 2009), the immune-medi-
ated pathogenesis of obesity, and obesity-related insulin
resistance (Feuerer et al., 2009; Winer et al., 2009) has recently
reinforced the concept that metabolism and proliferation of
lymphocytes can impact, at different levels, the control of inflam-Imation, autoimmunity, and immune-mediated disorders (Matar-
ese and La Cava, 2004; Matarese et al., 2008).
In conclusion, our findings may help to explain why Treg cells
proliferate in vivo but are anergic in vitro, and why for the expan-
sion of Treg cells in vitro there is the need of high doses of IL-2
(which activates mTOR kinase) together with the inhibitor of
mTOR kinase rapamycin for long-term cultures (Bour-Jordan
and Bluestone, 2009). Because the nutrient- and energy-sensing
leptin-mTOR pathway sets the threshold for responsiveness of
Treg cells, we hypothesize that the proliferating Treg cells
in vivo (Vukmanovic-Stejic et al., 2006) can sense changes in
the microenvironment when cultured in vitro, through the
leptin-mTOR pathway that makes Treg cells unresponsive to
TCR-mediated stimulation. More specifically, we hypothesize
that the high proliferative rate in vivo of Treg cells would asso-
ciate with continuous dynamic, oscillatory changes in mTOR
activity depending on the fluctuations in the composition of the
extracellular milieu—including amounts of leptin and nutrients
such as amino acids, glucose, and lipids. Alternatively, in vitro-
cultured Treg cells, after isolation, would be exposed to a ‘‘static’’
milieu of the culture media characterized by constantly high
concentration of leptin and nutrients (Sato et al., 2009), which
could sustain mTOR activation and thus inhibit its dynamic,
oscillatory changes required for Treg cell proliferation. The
acute, transient inhibition of mTOR (either with rapamycin or
nutrient starvation) in culture would reset in vitro the oscillatory
fluctuations in mTOR activity, rendering Treg cells able to
respond to TCR stimulation. This would explain why constant
mTOR inhibition, either with chronic rapamycin treatment ormmunity 33, 929–941, December 22, 2010 ª2010 Elsevier Inc. 939
Immunity
Leptin-mTOR Activation and Treg Cell AnergymTOR gene silencing, does not allow these dynamic changes
and inhibits Treg cell expansion. When IL-2 at very high concen-
tration is provided in vitro, the lowering of mTOR activity would
be reversed and allow the dynamic changes required for Treg
cells to expand.
Altogether, these findings indicate that the intracellular meta-
bolic and energy status controlled by leptin-mTOR may control
the choice between anergy and growth in Treg cells. This aspect
can have influences in modulating immune responses in autoim-
munity and transplantation.
EXPERIMENTAL PROCEDURES
Treg Cell Purification, Cultures, and Proliferation Assays
Human CD4+CD25hi and CD4+CD25 T cells were purified from PBMCs from
buffy coats of human healthy donors by high-performance cell sorting (MoFlo,
Dako) after staining with FITC anti-human CD4 (BD PharMingen, clone RPA-
T4), PE anti-human CD25 (BD PharMingen, clone M-A251), APC anti-human
CD127 (R&D Systems, clone 40131), or magnetic cell separation with
Dynabeads Regulatory T Cell Kit (Invitrogen). Soon after isolation,
CD4+CD25hiCD127 cells were rapidly cleaned with Detach reagent
(Invitrogen) to remove surface-bound CD25 mAb and beads. Antibody/
bead-free cells were 95%–98% pure by FACS analysis, and >95% expressed
FoxP3. For proliferation assays, purified cells were cultured (53 104 cells/well)
as previously described (De Rosa et al., 2007).
Mouse Treg cells were isolated with the Regulatory T Cell Isolation Kit (Mil-
tenyi Biotec, Gladbach, Germany) and by Automacs ProSeparator (Miltenyi
Biotec) or by high-performance cell sorting (MoFlo, Dako) for the expression
of EGFP-FoxP3. Cells were then stimulated with Dynabeads mouse anti-
CD3 plus anti-CD28 (0.5 bead/cell; 5 3 104 cells/well). Treg cells (>95%
pure by FACS analysis) were cultured as previously described (De Rosa
et al., 2007).
In Vitro Rapamycin, Leptin, Anti-Leptin, and UO126 Treatments
For transient mTOR inhibition, Treg and effector T cells were pretreated in vitro
for 1 hr with rapamycin (Sigma-Aldrich) or with UO126 (Promega Corporation)
at a final concentration of 100 nM or 10 mM, respectively. Cells were washed
extensively with serum-free culture medium and cultured as described before.
For chronic rapamycin treatment, the drugwas added (at final concentration of
100 nM) and left throughout the time of culture (72 hr). For in vitro leptin neutral-
ization experiments, human leptin-neutralizing mAb (R&D Systems, Minneap-
olis, MN) was used at a final concentration of 20 mg/ml; human recombinant
leptin was purchased from R&D Systems and was used at the final concentra-
tion of 100 ng/ml.
Immunoblots and Biochemical Analyses
Total cell lysates and immunoblot analysis were performed as previously
described (De Rosa et al., 2007). The antibodies used were the following:
anti-p27Kip-1, anti-phospho-mTOR, anti-m-TOR, anti-phospho p70S6K, anti-
p70S6K, anti-phospho-S6, anti-S6, anti-AMPK, anti-phospho-Lck (Tyr505),
anti-phospho-Zap-70, anti-phospho-AKT (Ser473), anti-AKT, anti-phospho-
STAT5 (Tyr694), and anti-STAT5 (all from Cell Signaling Technology, Beverly,
MA); anti-ERK1/2 and anti-phospho-ERK1/2 (all from Santa Cruz Biotech-
nology Inc., Santa Cruz, CA); and anti-FoxP3 (eBioscience). The filters were
also probed with a tubulin antibody (Sigma) to normalize for the amount of
loaded protein. All filters were quantified as previously described (De Rosa
et al., 2007).
Mice and In Vivo Experiments
8- to 10-week-old female leptin-deficient C57BL6/J-ob/ob (Lepob/ob),
C57BL6/J lean controls (wt), leptin-receptor-deficient C57BL/Ks-db/db
(Leprdb/db), and C57BL/Ks-db/+ lean controls (Leprdb/+) mice, and SJL/J
mice (H-2s) were purchased from Harlan Italy s.r.l. (Corezzana, Italy). B6.Cg-
Foxp3tm2tch/J (EGFP-FoxP3) were purchased from Jackson Laboratory; these
mice coexpress EGFP and the regulatory T cell-specific transcription factor
FoxP3 under the control of the endogenous promoter (Haribhai et al., 2007).940 Immunity 33, 929–941, December 22, 2010 ª2010 Elsevier Inc.Experiments were conducted in accordance with the animal welfare guidelines
under an approved protocol of the Istituto Superiore di Sanita`, Roma, Italy.
Mice were age matched for individual experiments and housed with a 12 hr
light-dark cycle in the animal facility at the Universita` di Napoli ‘‘Federico II.’’
Lepob/ob and wt mice were injected once intraperitoneally either with mouse
recombinant leptin (R&D Systems) dissolved in 200 ml of PBS at a dose of
100 mg/mouse or with rapamycin at a dose of 100 mg/mouse.
EGFP-FoxP3 reporter mice were daily treated with BrdU (1 mg/mouse) in
basal conditions and upon antigen immunization with CFA (complete Freund’s
adjuvant Difco, BD Diagnostics-Diagnostic Systems) and were treated with
a single dose of rapamycin (100 mg/mouse) or vehicle 12 hr before CFA priming
to follow proliferation of EGFP-FoxP3 cells overtime. Samples were obtained
at 5 days from tail veins or from draining lymph nodes at days 8 and 12, respec-
tively. For fasting experiments, daily treated with BrdU (1 mg/mouse), EGFP-
FoxP3 mice were fasted for 48 hr in the presence or not of exogenous mouse
recombinant leptin (R&D Systems) dissolved in 200 ml of PBS at a dose of
1 mg/g/mouse initial body weight twice daily at 9 am and 6 pm, and compared
with ad libitum fed mice (Lord et al., 1998). Draining lymph nodes from each
group of mice were harvested after 48 hr starvation and stained for BrdU.
Statistical Analyses
The Mann-Whitney U test was used for unrelated two-group analyses and the
Kruskal-Wallis ANOVA test for three or more groups, by means of StatView
software (Abacus Concepts Inc.). Results are expressed as mean ± SD.
p values < 0.05 were considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at doi:10.1016/j.
immuni.2010.11.024.
ACKNOWLEDGMENTS
G.M. is supported by grants from the EU Ideas Programme, ERC-Starting
Independent Grant ‘‘LeptinMS’’ n. 202579, and Telethon-JDRF Grant n.
GJT08004. A.L.C. is supported in part by the NIH grant n. AR53239. T.L.H.
is supported by the NIH Director’s Pioneer Award n. DP1OD006850. The
authors thank S. De Simone and F. D’Agnello for technical help in the cell sort-
ing MoFlo Core Facility. This work is dedicated to the memory of E. Papa and
S. Zappacosta.
Received: March 1, 2010
Revised: July 13, 2010
Accepted: October 22, 2010
Published online: December 9, 2010
REFERENCES
Abizaid, A., Gao, Q., and Horvath, T.L. (2006). Thoughts for food: Brain mech-
anisms and peripheral energy balance. Neuron 51, 691–702.
Araki, K., Turner, A.P., Shaffer, V.O., Gangappa, S., Keller, S.A., Bachmann,
M.F., Larsen, C.P., and Ahmed, R. (2009). mTOR regulates memory CD8
T-cell differentiation. Nature 460, 108–112.
Battaglia, M., Stabilini, A., and Roncarolo, M.G. (2005). Rapamycin selectively
expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105, 4743–4748.
Becker, T., Loch, G., Beyer, M., Zinke, I., Aschenbrenner, A.C., Carrera, P.,
Inhester, T., Schultze, J.L., and Hoch, M. (2010). FOXO-dependent regulation
of innate immune homeostasis. Nature 463, 369–373.
Bensinger, S.J.,Walsh, P.T., Zhang, J., Carroll, M., Parsons, R., Rathmell, J.C.,
Thompson, C.B., Burchill, M.A., Farrar, M.A., and Turka, L.A. (2004). Distinct
IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells.
J. Immunol. 172, 5287–5296.
Blouet, C., Ono, H., and Schwartz, G.J. (2008). Mediobasal hypothalamic p70
S6 kinase 1 modulates the control of energy homeostasis. Cell Metab. 8,
459–467.
Immunity
Leptin-mTOR Activation and Treg Cell AnergyBluestone, J.A., Mackay, C.R., O’Shea, J.J., and Stockinger, B. (2009). The
functional plasticity of T cell subsets. Nat. Rev. Immunol. 9, 811–816.
Bour-Jordan, H., and Bluestone, J.A. (2009). How suppressor cells led to
anergy, costimulation, and beyond. J. Immunol. 183, 4147–4149.
Burchill, M.A., Yang, J., Vang, K.B., and Farrar, M.A. (2007). Interleukin-2
receptor signaling in regulatory T cell development and homeostasis.
Immunol. Lett. 114, 1–8.
Chen, C., Liu, Y., Liu, R., Ikenoue, T., Guan, K.L., Liu, Y., and Zheng, P. (2008).
TSC-mTORmaintains quiescence and function of hematopoietic stem cells by
repressing mitochondrial biogenesis and reactive oxygen species. J. Exp.
Med. 205, 2397–2408.
Cota, D., Proulx, K., Smith, K.A., Kozma, S.C., Thomas, G., Woods, S.C., and
Seeley, R.J. (2006). Hypothalamic mTOR signaling regulates food intake.
Science 312, 927–930.
De Rosa, V., Procaccini, C., Calı`, G., Pirozzi, G., Fontana, S., Zappacosta, S.,
La Cava, A., and Matarese, G. (2007). A key role of leptin in the control of regu-
latory T cell proliferation. Immunity 26, 241–255.
Delgoffe, G.M., Kole, T.P., Zheng, Y., Zarek, P.E., Matthews, K.L., Xiao, B.,
Worley, P.F., Kozma, S.C., and Powell, J.D. (2009). The mTOR kinase differen-
tially regulates effector and regulatory T cell lineage commitment. Immunity 30,
832–844.
Faivre, S., Kroemer, G., and Raymond, E. (2006). Current development of
mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5, 671–688.
Feuerer, M., Herrero, L., Cipolletta, D., Naaz, A., Wong, J., Nayer, A., Lee, J.,
Goldfine, A.B., Benoist, C., Shoelson, S., and Mathis, D. (2009). Lean, but
not obese, fat is enriched for a unique population of regulatory T cells that
affect metabolic parameters. Nat. Med. 15, 930–939.
Gao, Q., and Horvath, T.L. (2008). Neuronal control of energy homeostasis.
FEBS Lett. 582, 132–141.
Gregori, S., Bacchetta, R., Passerini, L., Levings, M.K., and Roncarolo, M.G.
(2007). Isolation, expansion, and characterization of human natural and adap-
tive regulatory T cells. Methods Mol. Biol. 380, 83–105.
Haribhai, D., Lin,W., Relland, L.M., Truong, N.,Williams, C.B., andChatila, T.A.
(2007). Regulatory T cells dynamically control the primary immune response to
foreign antigen. J. Immunol. 178, 2961–2972.
Haxhinasto, S., Mathis, D., and Benoist, C. (2008). The AKT-mTOR Axis regu-
lates de novo differentiation of CD4+Foxp3+ cells. J. Exp. Med. 205, 565–574.
Kwon, G., Marshall, C.A., Pappan, K.L., Remedi, M.S., and McDaniel, M.L.
(2004). Signaling elements involved in the metabolic regulation of mTOR by
nutrients, incretins, and growth factors in islets. Diabetes 53 (Suppl 3 ),
S225–S232.
Laplante, M., and Sabatini, D.M. (2009). mTOR signaling at a glance. J. Cell
Sci. 122, 3589–3594.
Lord, G.M., Matarese, G., Howard, J.K., Baker, R.J., Bloom, S.R., and Lechler,
R.I. (1998). Leptin modulates the T-cell immune response and reverses starva-
tion-induced immunosuppression. Nature 394, 897–901.
Matarese, G., and La Cava, A. (2004). The intricate interface between immune
system and metabolism. Trends Immunol. 25, 193–200.
Matarese, G., De Rosa, V., and La Cava, A. (2008). Regulatory CD4 T cells:
Sensing the environment. Trends Immunol. 29, 12–17.IMcIntyre, C.C., Savasta, M., Kerkerian-Le Goff, L., and Vitek, J.L. (2004).
Uncovering the mechanism(s) of action of deep brain stimulation: Activation,
inhibition, or both. Clin. Neurophysiol. 115, 1239–1248.
Ng, W.F., Duggan, P.J., Ponchel, F., Matarese, G., Lombardi, G., Edwards,
A.D., Isaacs, J.D., and Lechler, R.I. (2001). Human CD4(+)CD25(+) cells:
A naturally occurring population of regulatory T cells. Blood 98, 2736–2744.
Sakaguchi, S., Yamaguchi, T., Nomura, T., and Ono, M. (2008). Regulatory
T cells and immune tolerance. Cell 133, 775–787.
Sato, K., Kondo, M., Sakuta, K., Hosoi, A., Noji, S., Sugiura, M., Yoshida, Y.,
and Kakimi, K. (2009). Impact of culture medium on the expansion of T cells
for immunotherapy. Cytotherapy 11, 936–946.
Sauer, S., Bruno, L., Hertweck, A., Finlay, D., Leleu, M., Spivakov, M., Knight,
Z.A., Cobb, B.S., Cantrell, D., O’Connor, E., et al. (2008). T cell receptor
signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl.
Acad. Sci. USA 105, 7797–7802.
Schubert, L.A., Jeffery, E., Zhang, Y., Ramsdell, F., and Ziegler, S.F. (2001).
Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell
activation. J. Biol. Chem. 276, 37672–37679.
Strauss, L., Czystowska, M., Szajnik, M., Mandapathil, M., andWhiteside, T.L.
(2009). Differential responses of human regulatory T cells (Treg) and effector
T cells to rapamycin. PLoS ONE 4, e5994.
Thomson, A.W., Turnquist, H.R., and Raimondi, G. (2009). Immunoregulatory
functions of mTOR inhibition. Nat. Rev. Immunol. 9, 324–337.
Thornton, A.M., and Shevach, E.M. (1998). CD4+CD25+ immunoregulatory
T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2
production. J. Exp. Med. 188, 287–296.
Vukmanovic-Stejic, M., Zhang, Y., Cook, J.E., Fletcher, J.M., McQuaid, A.,
Masters, J.E., Rustin, M.H., Taams, L.S., Beverley, P.C., Macallan, D.C., and
Akbar, A.N. (2006). Human CD4+CD25hi Foxp3+ regulatory T cells are derived
by rapid turnover of memory populations in vivo. J. Clin. Invest. 116, 2423–
2433.
Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R.,
Wang, Y., Zielenski, J., Mastronardi, F., et al. (2009). Normalization of obesity-
associated insulin resistance through immunotherapy. Nat. Med. 15, 921–929.
Woods, S.C., Seeley, R.J., and Cota, D. (2008). Regulation of food intake
through hypothalamic signaling networks involving mTOR. Annu. Rev. Nutr.
28, 295–311.
Yang, Q., and Guan, K.L. (2007). Expanding mTOR signaling. Cell Res. 17,
666–681.
Yu, A., Zhu, L., Altman, N.H., and Malek, T.R. (2009). A low interleukin-2
receptor signaling threshold supports the development and homeostasis of
T regulatory cells. Immunity 30, 204–217.
Zeiser, R., and Negrin, R.S. (2008). Interleukin-2 receptor downstream events
in regulatory T cells: Implications for the choice of immunosuppressive drug
therapy. Cell Cycle 7, 458–462.
Zheng, Y., Delgoffe, G.M., Meyer, C.F., Chan, W., and Powell, J.D. (2009).
Anergic T cells are metabolically anergic. J. Immunol. 183, 6095–6101.
Zhou, X., Bailey-Bucktrout, S.L., Jeker, L.T., Penaranda, C., Martı´nez-
Llordella, M., Ashby, M., Nakayama, M., Rosenthal, W., and Bluestone, J.A.
(2009). Instability of the transcription factor Foxp3 leads to the generation of
pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000–1007.mmunity 33, 929–941, December 22, 2010 ª2010 Elsevier Inc. 941
